NVSNovartis PharmaceuticalsRunning, no new patients
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Advanced Solid Tumors Which Are cMET-dependent
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 29 (final count)
- Started
- Jul 4, 2017
- Main results expected
- Jul 30, 2027
- Fully finished
- Jul 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Measured over: Day 1 up to 10 years, assessed every 12 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03040973 · record last updated 2026-09-09 · checked 2026-11-09 15:47 UTC